


## CLAIMS

1 A method of treating restless legs syndrome, comprising administering an effective amount of at least one adenosine A<sub>2A</sub> receptor antagonist to a patient in need thereof.


2 The method of treating restless legs syndrome according to claim 1 wherein the adenosine A<sub>2A</sub> receptor antagonist is a xanthine derivative or a pharmaceutically acceptable salt thereof.

3 The method of treating restless legs syndrome according to claim 2 wherein the xanthine derivative is represented by the following formula (I):




(I)

wherein R<sup>1</sup>, R<sup>2</sup>, and R<sup>3</sup> independently represent hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; R<sup>4</sup> represents cycloalkyl, -(CH<sub>2</sub>)<sub>n</sub>-R<sup>5</sup> (in which R<sup>5</sup> represents substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4) or




{in which Y<sup>1</sup> and Y<sup>2</sup> independently represent hydrogen, halogen or lower alkyl; and Z represents substituted or unsubstituted aryl, or




(in which  $R^6$  represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro or amino; and  $m$  represents an integer of 1 to 3)); and  $X^1$  and  $X^2$  independently represent O or S.

4 The method of treating restless legs syndrome according to claim 2 wherein the xanthine derivative is represented by the following formula (I-A):




(I-A)

wherein  $R^{1a}$  and  $R^{2a}$  independently represent methyl or ethyl;  $R^{3a}$  represents hydrogen or lower alkyl; and  $Z^a$  represents



(in which at least one of  $R^7$ ,  $R^8$  and  $R^9$  represents lower alkyl or lower alkoxy and the others represent hydrogen;  $R^{10}$  represents hydrogen or lower alkyl) or



(in which R<sup>6</sup> and m have the same meanings as defined above, respectively).

5 The method of treating restless legs syndrome according to claim 2 wherein the xanthine derivative is (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine.

6 Use of the adenosine A<sub>2A</sub> receptor antagonist described in any one of claims 1 to 5 for manufacturing a therapeutic agent for restless legs syndrome.

7 A therapeutic agent for restless legs syndrome comprising the adenosine A<sub>2A</sub> receptor antagonist described in any one of claims 1 to 5.

8 A method of treating nocturnal myoclonus, comprising administering an effective amount of the adenosine A<sub>2A</sub> receptor antagonist described in any one of claims 1 to 5 to a patient in need thereof.